These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24154719)

  • 1. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.
    Disis ML; Gad E; Herendeen DR; Lai VP; Park KH; Cecil DL; O'Meara MM; Treuting PM; Lubet RA
    Cancer Prev Res (Phila); 2013 Dec; 6(12):1273-82. PubMed ID: 24154719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
    Park JM; Terabe M; Sakai Y; Munasinghe J; Forni G; Morris JC; Berzofsky JA
    J Immunol; 2005 Apr; 174(7):4228-36. PubMed ID: 15778385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
    Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
    Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.
    Cecil D; Park KH; Curtis B; Corulli L; Disis MN
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.
    Cecil DL; Holt GE; Park KH; Gad E; Rastetter L; Childs J; Higgins D; Disis ML
    Cancer Res; 2014 May; 74(10):2710-8. PubMed ID: 24778415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.
    Phan-Lai V; Dang Y; Gad E; Childs J; Disis ML
    Clin Cancer Res; 2016 May; 22(9):2207-16. PubMed ID: 26660518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
    Knutson KL; Disis ML
    Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.
    Li Y; Zhang Y; Hill J; Kim HT; Shen Q; Bissonnette RP; Lamph WW; Brown PH
    Br J Cancer; 2008 Apr; 98(8):1380-8. PubMed ID: 18362934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer.
    Céfaï D; Morrison BW; Sckell A; Favre L; Balli M; Leunig M; Gimmi CD
    Int J Cancer; 1999 Oct; 83(3):393-400. PubMed ID: 10495433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
    Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of rat-neu
    Sow HS; Benonisson H; Brouwers C; Linssen MM; Camps M; Breukel C; Claassens J; van Hall T; Ossendorp F; Fransen MF; Verbeek JS
    Sci Rep; 2020 Mar; 10(1):3933. PubMed ID: 32127568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
    JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells
    Cecil DL; Slota M; O'Meara MM; Curtis BC; Gad E; Dang Y; Herendeen D; Rastetter L; Disis ML
    Clin Cancer Res; 2017 Jul; 23(13):3396-3404. PubMed ID: 28039264
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.